Join us this Thursday, 2/27, for an exciting look at the next generation of blood-based predictive biomarkers for therapy selection.

A novel, highly accurate liquid biopsy-based glycoproteomic predictor of checkpoint inhibitor treatment benefit in advanced non-small cell lung cancer

Get in touch